ArticlePloS one2013
Enhanced Chemokine Receptor Expression on Leukocytes of Patients with Alzheimer's Disease.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 60 citations in OpenAlex.
- Blood-based immunophenotyping of T cell profiles in patients with neurodegenerative disorders.Alzheimer's research & therapy · 2026Article
- Plasma ceramide mediates the association of peripheral T cells with Alzheimer's disease.Journal of advanced research · 2026Article
- Targeting of specific neuronal types in the non-human primate brain by using a murine CD25-specific recombinant immunotoxin.Scientific reports · 2026Article
- Inflammatory Mediators of Alzheimer's Disease Characterized in a Mouse Model (APP/PS1).NeuroSci · 2026Article
- Exploring inflammation-related protein expression and its relationship with TSPO PET in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Identification of UBE2N as a biomarker of Alzheimer's disease by combining WGCNA with machine learning algorithms.Scientific reports · 2025Article
- T Cells Trafficking into the Brain in Aging and Alzheimer's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024Review
- The intricate role of CCL5/CCR5 axis in Alzheimer disease.Journal of neuropathology and experimental neurology · 2023Review
- Convergent transcriptomic and genomic evidence supporting a dysregulation of CXCL16 and CCL5 in Alzheimer's disease.Alzheimer's research & therapy · 2023Article
- Revisiting the neuroinflammation hypothesis in Alzheimer's disease: a focus on the druggability of current targets.Frontiers in pharmacology · 2023Review
- Telomerase reverse transcriptase and neurodegenerative diseases.Frontiers in immunology · 2023Review
- Ribosomal proteins are blood biomarkers and associated with CD4+ T cell activation in Alzheimer's disease: a study based on machine learning strategies and scRNA-Seq data validation.American journal of translational research · 2023Article
- SARS-CoV-2 infection increases the gene expression profile for Alzheimer's disease risk.Molecular therapy. Methods & clinical development · 2022Article
- Acquired immunity and Alzheimer's disease.Journal of biomedical research · 2022Article
- Targeting C-C Chemokine Receptor 5: Key to Opening the Neurorehabilitation Window After Ischemic Stroke.Frontiers in cellular neuroscience · 2022Review
- Insights into T-cell dysfunction in Alzheimer's disease.Aging cell · 2021Review
- Article
- Hyperactivation of monocytes and macrophages in MCI patients contributes to the progression of Alzheimer's disease.Immunity & ageing : I & A · 2021Article
- Identification of Hub Genes and Immune Cell Infiltration Characteristics in Alzheimer's Disease.Journal of healthcare engineering · 2021Article
- Entanglement of CCR5 and Alzheimer's Disease.Frontiers in aging neuroscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
Abstract
Although primarily a neurological complaint, systemic inflammation is present in Alzheimer's Disease, with higher than normal levels of proinflammatory cytokines and chemokines in the periphery as well as the brain. A gradient of these factors may enhance recruitment of activated immune cells into the brain via chemotaxis. Here, we investigated the phenotypes of circulating immune cells in AD patients with multi-colour flow cytometry to determine whether their expression of chemokine receptors is consistent with this hypothesis. In this study, we confirmed our previously reported data on the shift of early- to late-differentiated CD4+ T-cells in AD patients. The percentage of cells expressing CD25, a marker of acute T-cell activation, was higher in patients than in age-matched controls, and percentages of CCR6+ cells were elevated. This chemokine receptor is primarily expressed on pro-inflammatory memory cells and Th17 cells. The proportion of cells expressing CCR4 (expressed on Th2 cells) and CCR5 (Th1 cells and dendritic cells) was also greater in patients, and was more pronounced on CD4+ than CD8+ T-cells. These findings allow a more detailed insight into the systemic immune status of patients with Alzheimer's disease and suggest possible novel targets for immune therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.